Eli Lilly just gave investors several reasons to cheer.
The Food and Drug Administration (FDA) has reaffirmed that Mounjaro and Zepbound are no longer in shortage following a ...
As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...
The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products ... have to halt ...
Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with ...
What Eli Lilly ( LLY -0.05%) is doing is far more impressive. The company has been increasing its dividend at a high rate, ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 488.46% and ...
Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback